T o respond to the growing call for more evidenced-based medicine, the American Heart Association (AHA) commissions guidelines on various clinical topics and endeavors to keep them as current as possible. The prior aneurysmal subarachnoid hemorrhage (aSAH) guidelines, sponsored by the AHA Stroke Council, were previously issued in 1994 1 and 2009. 2 The 2009 guidelines covered literature through November 1, 2006 . 2 The present guidelines primarily cover literature published between November 1, 2006 , and May 1, 2010, but the writing group has strived to place these data in the greater context of the prior publications and recommendations. In cases in which new data covered in this review have resulted in a change in a prior recommendation, this is explicitly noted.
aSAH is a significant cause of morbidity and mortality throughout the world. Although the incidence of aSAH varies widely among populations, perhaps because of genetic differences, competing burden of disease, and issues of case ascertainment, at the very least, a quarter of patients with aSAH die, and roughly half of survivors are left with some persistent neurological deficit. That said, case-fatality rates appear to be falling, and increasing data suggest that early aneurysm repair, together with aggressive management of complications such as hydrocephalus and delayed cerebral ischemia (DCI), is leading to improved functional outcomes. These improvements underscore the need to continually reassess which interventions provide the greatest benefit to patients.
Although large, multicenter, randomized trial data confirming effectiveness are usually lacking for many of the interventions discussed, the writing group did its best to summarize the strength of the existing data and make practical recommendations that clinicians will find useful in the day-to-day management of aSAH. This review does not discuss the multitude of ongoing studies. Many of these can be found at http://www.strokecenter.org/trials/. The mechanism of reviewing the literature, compiling and analyzing the data, and determining the final recommendations to be made is identical to the 2009 version of this guideline. 2 The members of the writing group were selected by the AHA to represent the breadth of healthcare professionals who must manage these patients. Experts in each field were screened for important conflicts of interest and then met by telephone to determine subcategories to evaluate. These subcategories included incidence, risk factors, prevention, natural history and outcome, diagnosis, prevention of rebleeding, surgical and endovascular repair of ruptured aneurysms, systems of care, anesthetic management during repair, management of vasospasm and DCI, management of hydrocephalus, management of seizures, and management of medical complications. Together, these categories were thought to encompass all of the major areas of disease management, including prevention, diagnosis, and treatment. Each subcategory was led by 1 author, with 1 or 2 additional coauthors who made contributions. Full MEDLINE searches were conducted independently by each author and coauthor of all English-language papers on treatment of relevant human disease. Drafts of summaries and recommendations were circulated to the entire writing group for feedback. A conference call was held to discuss controversial issues. Sections were revised and merged by the writing group chair. The resulting draft was sent to the entire writing group for comment. Comments were incorporated into the draft by the writing group chair and vice chair, and the entire writing group was asked to approve the final draft. The chair and vice chair revised the document in response to peer review, and the document was again sent to the entire writing group for additional suggestions and approval.
The recommendations follow the AHA Stroke Council's methods of classifying the level of certainty of the treatment effect and the class of evidence (Tables 1 and 2 ). All Class I recommendations are listed in Table 3 . All new or revised recommendations are listed in Table 4 .
Incidence and Prevalence of aSAH
Considerable variation in the annual incidence of aSAH exists in different regions of the world. A World Health Organization study found a 10-fold variation in the ageadjusted annual incidence in countries in Europe and Asia, from 2.0 cases per 100 000 population in China to 22.5 cases per 100 000 in Finland. 3 A later systematic review supported a high incidence of aSAH in Finland and Japan, a low incidence in South and Central America, and an intermediate incidence of 9.1 per 100 000 population in other regions. 4 In a more recent systematic review of population-based studies, the incidence of aSAH ranged from 2 to 16 per 100 000. 5 In that review, the pooled age-adjusted incidence rate of aSAH in low-to middle-income countries was found to be almost double that of high-income countries. 5 Although some reports have suggested the incidence of aSAH in the United States to be 9.7 per 100 000, 6 the 2003 Nationwide Inpatient Sample provided an annual estimate of 14.5 discharges for aSAH per 100 000 adults. 7 Because death resulting from aSAH often occurs before hospital admission (an estimated 12% to 15% of cases), 8, 9 the true incidence of aSAH might be even higher. Although a number of population-based studies have indicated that the incidence of aSAH has remained relatively stable over the past 4 decades, 5,10 -16 a recent review that adjusted for age and sex suggested a slight decrease in incidence between 1950 and 2005 for regions other than Japan, South and Central America, and Finland. 4 These data are consistent with studies that show that the incidence of aSAH increases with age, with a typical average age of onset in adults Ն50 years of age. 3, 7, 17, 18 aSAH is relatively uncommon in children; incidence rates increase as children get older, with incidence ranging from 0.18 to 2.0 per 100 000. 4 , 19 The majority of studies also indicate a higher incidence of aSAH in women than in men. 7,11-13,20 -22 Most recent pooled figures report the incidence in women to be 1.24 (95% confidence interval, 1.09 -1.42) times higher than in men. 4 This is lower than a previous estimate of 1.6 (95% confidence interval, 1.1-2.3) for the years 1960 to 1994. 23 Evidence of a sex-age effect on aSAH incidence has emerged from pooled study data, with a higher incidence reported in younger men (25-45 years of age), women between 55 and 85 years of age, and men Ͼ85 years of age. 4 Differences in incidence of aSAH by race and ethnicity appear to exist.
Blacks and Hispanics have a higher incidence of aSAH than white Americans. 6, 24, 25 
Risk Factors for and Prevention of aSAH
Behavioral risk factors for aSAH include hypertension, smoking, alcohol abuse, and the use of sympathomimetic drugs (eg, cocaine). In addition to female sex (above), the risk of aSAH is increased by the presence of an unruptured cerebral aneurysm (particularly those that are symptomatic, larger in size, and located either on the posterior communicating artery or the vertebrobasilar system), a history of previous aSAH (with or without a residual untreated aneurysm), a history of familial aneurysms (at least 1 first-degree family member with an intracranial aneurysm, and especially if Ն2 firstdegree relatives are affected) and family history of aSAH, 26, 27 and certain genetic syndromes, such as autosomal dominant polycystic kidney disease and type IV Ehlers-Danlos syndrome. 28, 29 Novel findings reported since publication of the previous version of these guidelines include the following: (1) Aneurysms in the anterior circulation appear to be more prone to rupture in patients Ͻ55 years of age, whereas posterior communicating aneurysms ruptured more frequently in men, and basilar artery aneurysm rupture is associated with lack of use of alcohol. 30 ( 2) The size at which Table 1 
. Applying Classification of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
aneurysms rupture appears to be smaller in those patients with the combination of hypertension and smoking than in those with either risk factor alone. 31 (3) Significant life events such as financial or legal problems within the past month may increase the risk of aSAH. 32 (4) Aneurysm size Ͼ7 mm has been shown to be a risk factor for rupture. 33 (5) There does not appear to be an increased risk of aSAH in pregnancy, delivery, and puerperium. 34, 35 Inflammation appears to play an important role in the pathogenesis and growth of intracranial aneurysms. 36 Prominent mediators include the nuclear factor -light-chain enhancer of activated B cells (NF-B), 37 tumor necrosis factor, macrophages, and reactive oxygen species. Although there are no controlled studies in humans, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin") 38 and calcium channel blockers may retard aneurysm formation through the inhibition of NF-B and other pathways. Among the risk factors for aSAH, clearly attributable and modifiable risks are very low body mass index, smoking, and high alcohol consumption. 31, 39, 40 Yet, despite marked improvements in the treatment of hypertension and hyperlipidemia and the decrease in rates of smoking over time, the incidence of aSAH has not changed appreciably in 30 years. 16 It is possible that diet increases the risk of stroke in general and aSAH in particular. In an epidemiological study of Finnish smokers who were monitored for Ͼ13 years, increased consumption of yogurt (but not all dairy products) was associated with a higher risk of aSAH. 41 Greater vegetable consumption is associated with a lower risk of stroke and aSAH. 42 Higher coffee and tea consumption 43 and higher magnesium consumption 44 were associated with reduced risk of stroke overall but did not change the risk of aSAH.
Predicting the growth of an individual intracranial aneurysm and its potential for rupture in a given patient remains problematic. When followed up on magnetic resonance imaging, larger aneurysms (Ն8 mm in diameter) tended to grow more over time, 45 which implies a higher risk of rupture. Several characteristics of aneurysm morphology (such as a bottleneck shape 46 and the ratio of size of aneurysm to parent vessel 47, 48 ) have been associated with rupture status, but how these might be applied to individual patients to predict future aneurysmal rupture is still unclear. 33 Variability within each patient is unpredictable at this time, but such intraindividual variability markedly changes the risk of aneurysm detection and rupture and may attenuate the benefits of routine screening in high-risk patients. 49 Given such uncertainties, younger age, longer life expectancy, and higher rate of rupture all make treatment of unruptured aneurysms more likely to be cost-effective and reduce morbidity and mortality. 50 Two large observational studies of familial aneurysms suggest that screening these patients may also be cost-effective in preventing aSAH and improving quality of life. 26, 27 Smaller studies have suggested that screening of those with 1 first-degree relative with aSAH may be justified as well, but it is far less clear whether patients who underwent treatment for a previous aSAH require ongoing screening. 51, 52 In the Cerebral Aneurysm Rerupture After Treatment (CARAT) study, recurrent aSAH was predicted by incomplete obliteration of the aneurysm and occurred a median of 3 days after treatment but rarely after 1 year. 53 Repeated noninvasive screening at later times may not be cost-effective, increase life expectancy, or improve quality of life in unselected patients. 54 Patients with adequately obliterated aneurysms after aSAH have a low risk of recurrent aSAH for at least 5 years, 55 
Natural History and Outcome of aSAH
Although the case fatality of aSAH remains high worldwide, 5 mortality rates from aSAH appear to have declined in industrialized nations over the past 25 years. 9, 11, 15, 58, 59 One study in the United States reported a decrease of Ϸ1% per year from 1979 to 1994. 60 Others have shown that case fatality rates decreased from 57% in the mid-1970s to 42% in the mid-1980s, 11 whereas rates from the mid-1980s to 2002 are reported to be anywhere from 26% to 36%. 6, 12, 13, 18, 20, 61, 62 Mortality rates vary widely across published epidemiological studies, ranging from 8% to 67%. 59 Regional variations become apparent when numbers from different studies are compared. The median mortality rate in epidemiological studies from the United States has been 32% versus 43% to 44% in Europe and 27% in Japan. 59 These numbers are based on studies that did not always fully account for cases of prehospital death. This is an important consideration because the observed decrease in case fatality is related to improvements in survival among hospitalized patients with aSAH. The mean age of patients presenting with aSAH is increasing, which has been noted to have a negative impact on survival rates. 59 Sex and racial variations in survival may also play a role in the variable rates, with some studies suggesting higher mortality in women than in men 9,11,60 and higher mortality in blacks, American Indians/Alaskan Natives, and Asians/Pacific Islanders than in whites. 63 Available population-based studies offer much less information about the functional outcome of survivors. Rates of persistent dependence of between 8% and 20% have been reported when the modified Rankin Scale is used. 59 Although not population based, trial data show a similar picture, with 12% of patients in the International Subarachnoid Aneurysm Trial (ISAT) showing significant lifestyle restrictions (modified Rankin Scale 3) and 6.5% being functionally dependent (modified Rankin Scale score of 4 -5) 1 year after aSAH. Furthermore, scales that are relatively insensitive to cognitive impairment, behavioral changes, social readjustment, and energy level may substantially underestimate the effect of aSAH on the function and quality of life of surviving patients. Multiple studies using diverse designs have consistently demonstrated that intellectual impairment is very prevalent after aSAH. Although cognitive function tends to improve over the first year, 64 global cognitive impairment is still present in Ϸ20% of aSAH patients and is associated with poorer functional recovery and lower quality of life. 65 Cognitive deficits and functional decline are often compounded by mood disorders (anxiety, depression), fatigue, and sleep disturbances. 66 Therefore, scales assessing well-being and quality of life can be particularly useful in the integral assessment of patients with aSAH, even among those who regain functional independence. 67, 68 Behavioral and psychosocial difficulties, as well as poor physical and mental endurance, are some of the most commonly encountered factors accounting for the inability of otherwise independent patients to return to their previous occupations. 66, 68 Much remains to be learned about the causes of cognitive and functional deficits after aSAH and the best methods to assess intellectual outcome and functional recovery in these patients. The severity of clinical presentation is the strongest prognostic indicator in aSAH. Initial clinical severity can be 69, 70 Aneurysm rebleeding is another major predictor of poor outcome, as discussed in a later section. Other factors predictive of poor prognosis include older age, preexisting severe medical illness, global cerebral edema on computed tomography (CT) scan, intraventricular and intracerebral hemorrhage, symptomatic vasospasm, delayed cerebral infarction (especially if multiple), hyperglycemia, fever, anemia, and other systemic complications such as pneumonia and sepsis. [71] [72] [73] [74] [75] [76] [77] Certain aneurysm factors, such as size, location, and complex configuration, may increase the risk of periprocedural complications and affect overall prognosis. 78 Treatment in high-volume centers with availability of neurosurgical and endovascular services may be associated with better outcomes. 79 -81 Natural History and Outcome of aSAH: Recommendations 
Clinical Manifestations and Diagnosis of aSAH
The clinical presentation of aSAH is one of the most distinctive in medicine. The hallmark of aSAH in a patient who is awake is the complaint "the worst headache of my life," which is described by Ϸ80% of patients who can give a history. 82 This headache is characterized as being extremely sudden and immediately reaching maximal intensity (thunderclap headache). A warning or sentinel headache that precedes the aSAH-associated ictus is also reported by 10% to 43% of patients. 83, 84 This sentinel headache increases the odds of early rebleeding 10-fold. 85 Most intracranial aneurysms remain asymptomatic until they rupture. aSAH can occur during physical exertion or stress. 86 Nevertheless, in a review of 513 patients with aSAH, the highest incidence of rupture occurred while patients were engaged in their daily routines, in the absence of strenuous physical activity. 87 The onset of headache may be associated with Ն1 additional signs and symptoms, including nausea and/or vomiting, stiff neck, photophobia, brief loss of consciousness, or focal neurological deficits (including cranial nerve palsies). In a retrospective study of 109 patients with proven aSAH, headache was present in 74%, nausea or vomiting in 77%, loss of consciousness in 53%, and nuchal rigidity in 35%. 88 As many as 12% of patients die before receiving medical attention. Despite the classic presentation of aSAH, individual findings occur inconsistently, and because the type of headache from aSAH is sufficiently variable, misdiagnosis or delayed diagnosis is common. Before 1985, misdiagnosis of aSAH occurred in as many as 64% of cases, with more recent data suggesting a misdiagnosis rate of Ϸ12%. 89, 90 Misdiagnosis was associated with a nearly 4-fold higher likelihood of death or disability at 1 year in patients with minimal or no neurological deficit at the initial visit. 89 The most common diagnostic error is failure to obtain a noncontrast head CT scan. 89, [91] [92] [93] In a small subset of patients, a high degree of suspicion based on clinical presentation will lead to the correct diagnosis despite normal head CT and cerebrospinal fluid test results, as shown in a recent study in which 1.4% of patients were diagnosed with aSAH only after vascular imaging techniques were used. 94 Patients may report symptoms consistent with a minor hemorrhage before a major rupture, which has been called a sentinel bleed or warning leak. 83 , 84 The majority of these minor hemorrhages occur within 2 to 8 weeks before overt aSAH. The headache associated with a warning leak is usually milder than that associated with a major rupture, but it may last a few days. 95, 96 Nausea and vomiting may occur, but meningismus is uncommon after a sentinel hemorrhage. Among 1752 patients with aneurysm rupture from 3 series, 340 (19.4%; range, 15%-37%) had a history of a sudden severe headache before the event that led to admission. 82, 95, 97 The importance of recognizing a warning leak cannot be overemphasized. Headache is a common presenting chief complaint in the emergency department, and aSAH accounts for only 1% of all headaches evaluated in the emergency department. 92 Therefore, a high index of suspicion is warranted, because diagnosis of the warning leak or sentinel hemorrhage before a catastrophic rupture may be lifesaving. 93 Seizures may occur in up to 20% of patients after aSAH, most commonly in the first 24 hours and more commonly in aSAH associated with intracerebral hemorrhage, hypertension, and middle cerebral and anterior communicating artery aneurysms. 98, 99 Noncontrast head CT remains the cornerstone of diagnosis of aSAH; since publication of the previous version of these guidelines, 1,2 there have been only minor changes in imaging technology for this condition. The sensitivity of CT in the first 3 days after aSAH remains very high (close to 100%), after which it decreases moderately during the next few days. 2,100 After 5 to 7 days, the rate of negative CT increases sharply, and lumbar puncture is often required to show xanthochromia. However, advances in magnetic resonance imaging of the brain, particularly the use of fluid-attenuated inversion recovery, proton density, diffusion-weighted imaging, and gradient echo sequences, [101] [102] [103] can often allow the diagnosis of aSAH to be made when a head CT scan is negative and there is clinical suspicion of aSAH, possibly avoiding the need for lumbar puncture. The role of magnetic resonance imaging in perimesencephalic aSAH is controversial. 104 Indications for magnetic resonance angiography in aSAH are still few because of limitations with routine availability, logistics (including difficulty in scanning acutely ill patients), predisposition to motion artifact, patient compliance, longer study time, and cost. Aneurysms Ͻ3 mm in size continue to be unreliably demonstrated on computed tomographic angiography (CTA), 105, 106 and this generates continued controversy in the case of CTA-negative aSAH. 107 In cases of perimesencephalic subarachnoid hemorrhage (SAH), some authors claim that a negative CTA result is sufficient to rule out aneurysmal hemorrhage and that cerebral angiography is not required, but this is controversial. In 1 study, the overall interobserver and intraobserver agreement for nonaneurysmal perimesencephalic hemorrhage was good, but there was still a level of disagreement among observers, which suggests that clinicians should be cautious when deciding whether to pursue follow-up imaging. 108 In another study, 109 a negative CTA result reliably excluded aneurysms when head CT showed the classic perimesencephalic SAH pattern or no blood. Digital subtraction angiography (DSA) was indicated if there was a diffuse aneurysmal pattern of aSAH, and repeat delayed DSA was required if the initial DSA findings were negative, which led to the detection of a small aneurysm in 14% of cases. When the blood is located in the sulci, CTA should be scrutinized for vasculitis, and DSA is recommended for confirmation. 109 Others have shown that CTA may not reveal small aneurysms and that 2-and 3-dimensional cerebral angiography should be performed, especially when the hemorrhage is accompanied by loss of consciousness. 110 In cases of diffuse aSAH pattern, most agree that negative CTA should be followed by 2-and 3-dimensional cerebral angiography. In older patients with degenerative vascular diseases, CTA can replace catheter cerebral angiography in most cases if the image quality is excellent and analysis is performed carefully. 111 Overlying bone can be problematic with CTA, especially at the skull base. A new technique, CTA-MMBE (multisection CTA combined with matched mask bone elimination), is accurate in detecting intracranial aneurysms in any projection without superimposed bone. 112 CTA-MMBE has limited sensitivity in detecting very small aneurysms. The data suggest that DSA and 3-dimensional rotational angiography can be limited to the vessel harboring the ruptured aneurysm before endovascular treatment after detection of a ruptured aneurysm with CTA. Another new technique, dual-energy CTA, has diagnostic image quality at a lower radiation dose than digital subtraction CTA and high diagnostic accuracy compared with 3-dimensional DSA (but not 2-dimensional DSA) in the detection of intracranial aneurysms. 113 Cerebral angiography is still widely used in the investigation of aSAH and the characterization of ruptured cerebral aneurysms. Although CTA is sometimes considered sufficient on its own when an aneurysm will be treated with surgical clipping, 114 substantial controversy remains about the ability of CTA to determine whether or not an aneurysm is amenable to endovascular therapy. [115] [116] [117] [118] [119] [120] In 1 series, 115 95.7% of patients with aSAH were referred for treatment on the basis of CTA. In 4.4% of patients, CTA did not provide enough information to determine the best treatment, and those patients required DSA; 61.4% of patients were referred to endovascular treatment on the basis of CTA; and successful coiling was achieved in 92.6%. The authors concluded that CTA with a 64-slice scanner is an accurate tool for detecting and characterizing aneurysms in acute aSAH and that CTA is useful in deciding whether to coil or clip an aneurysm. 115 Partial volume averaging phenomena may artificially widen the aneurysmal neck and may lead to the erroneous conclusion that an aneurysm cannot be treated by endovascular coiling. This controversy is likely caused by the different technological specifications (16-versus 64-detector rows), slice thickness, and data processing algorithms of various CT systems, which have different spatial resolutions. Threedimensional cerebral angiography is more sensitive for detecting aneurysms than 2-dimensional angiography. 121 , 122 The combination of 3-and 2-dimensional cerebral angiography usually provides the best morphological depiction of aneurysm anatomy with high spatial resolution, and it is, of course, always used in preparation for endovascular therapy.
Flat-panel volumetric CT is a relatively recent development that allows the generation of CT-like images from a rotational 3-dimensional spin of the x-ray gantry in the angiography room. For the moment, it has no substantial role in the initial diagnosis of aSAH because its spatial and contrast resolutions are not high enough 123 ; however, this technology can be used intraprocedurally during embolizations to rule out hydrocephalus. 124 Recently, radiation dose has emerged as an important and worrisome consideration for patients with SAH. 125 , 126 The combination of noncontrast head CT for the diagnosis of aSAH, confirmation of ventriculostomy placement, investigation of neurological changes, CTA for aneurysmal diagnosis, CTA and CT perfusion for recognition of vasospasm, and catheter cerebral angiography for aneurysm embolization and then for endovascular therapy of vasospasm can result in substantial radiation doses to the head, with possible risk of radiation injury, such as scalp erythema and alopecia. Although some or all of these radiological examinations are often necessary, efforts need to be made to reduce the amount of radiation exposure in patients with aSAH whenever possible. 
Clinical Manifestations and Diagnosis of aSAH: Recommendations

Medical Measures to Prevent Rebleeding After aSAH
Aneurysm rebleeding is associated with very high mortality and poor prognosis for functional recovery in survivors. The risk of rebleeding is maximal in the first 2 to 12 hours, with reported rates of occurrence between 4% and 13.6% within the first 24 hours. [127] [128] [129] [130] In fact, more than one third of rebleeds occur within 3 hours and nearly half within 6 hours of symptom onset, 131 and early rebleeding is associated with worse outcome than later rebleeding. 132 Factors associated with aneurysm rebleeding include longer time to aneurysm treatment, worse neurological status on admission, initial loss of consciousness, previous sentinel headaches (severe headaches lasting Ͼ1 hour that do not lead to the diagnosis of aSAH), larger aneurysm size, and possibly systolic blood pressure Ͼ160 mm Hg. 87, 129, 130 Genetic factors, although related to the occurrence of intracranial aneurysms, do not appear to be related to an increased incidence of rebleeding. 133 Early treatment of the ruptured aneurysm can reduce the risk of rebleeding. 71 Among patients who present in a delayed manner and during the vasospasm window, delayed obliteration of aneurysm is associated with a higher risk of rebleeding than early obliteration of aneurysm. 134 There is general agreement that acute hypertension should be controlled after aSAH and until aneurysm obliteration, but parameters for blood pressure control have not been defined. A variety of titratable medications are available. Nicardipine may give smoother blood pressure control than labetalol 135 and sodium nitroprusside, 136 although data showing different clinical outcomes are lacking. Although lowering cerebral perfusion pressure may lead to cerebral ischemia, a cohort study of neurologically critically ill patients did not find an association between use of nicardipine and reduced brain oxygen tension. 137 Clevidipine, a very short-acting calcium channel blocker, is another option for acute control of hypertension, but data for aSAH are lacking at this time.
Antifibrinolytic therapy has been shown to reduce the incidence of aneurysm rebleeding when there is a delay in aneurysm obliteration. One referral center instituted a policy of short-term use of aminocaproic acid to prevent rebleeding during patient transfer. Such use led to a decreased incidence in rebleeding without increasing the risk of DCI, but 3-month clinical outcomes were not affected. 138 There was an increased risk of deep venous thrombosis but not pulmonary embolism. Neither aminocaproic acid nor tranexamic acid is approved by the US Food and Drug Administration for prevention of aneurysm rebleeding. 
Medical Measures to Prevent Rebleeding
Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms
Microsurgical clip obliteration of intracranial aneurysms was the primary modality of treatment before 1991, when Guglielmi first described occlusion of an aneurysm by an endovascular approach with electrolytically detachable coils. 139 With advancements in both microsurgical and endovascular approaches, algorithms to determine the proper patient population and aneurysmal characteristics for each treatment are continually undergoing refinement. The only multicenter randomized trial comparing microsurgical and endovascular repair, ISAT, randomized 2143 of 9559 screened patients with aSAH across 42 neurosurgical centers. 140 For a patient to be considered eligible for the trial, neurosurgeons and interventionalists had to agree that the aneurysm was comparably suitable for treatment with either modality. Primary outcomes included death or dependent living, and secondary outcomes included risk of seizures and risk of rebleeding. Initial 1-year outcomes revealed a reduction in death and disability from 31% in the microsurgery arm to 24% in the endovascular arm (relative risk reduction, 24%). 141 This difference was mainly driven by a decrease in the rate of disability among survivors 16% in the endovascular arm and 22% in the craniotomy arm) and was likely attributable at least in part to the greater incidence of technical complications in the clipping (19%) versus the coiling (8%) arms and the longer time needed to secure the aneurysm. 142 , 143 The risk of epilepsy and significant cognitive decline was also reduced in the endovascular group, but the incidence of late rebleeding (2.9% after endovascular repair versus 0.9% after open surgery) was higher in the endovascular arm, and only 58% of coiled aneurysms were completely obliterated compared with 81% of clipped aneurysms. 140 A large retrospective analysis found that the rate of incomplete occlusion and subsequent aneurysm recurrence depended critically on neck diameter and dome size. 139 It can also be difficult to achieve complete obliteration in very small aneurysms (Ͻ3 mm), with 1 study reporting no coils deployed in 5% of cases, residual dome filling or a neck remnant in 30%, and a higher procedural complication rate than in larger aneurysms. 144 Although the complete obliteration rate can be increased by the addition of a high-porosity stent, this has been associated with an increased risk of complications, especially in patients with SAH, in large part because of the need for periprocedural dual-antiplatelet therapy to prevent arterial thromboembolism. 145 Whether low-porosity flow-diverting stents with or without coils represent a better option for many or most of those presenting with SAH from saccular aneurysms remains to be studied, but these stents make more conceptual sense for use in the patient with a dissecting aneurysm, in whom vessel sacrifice is not an option and microsurgical solutions carry higher risk.
Another approach to increasing complete obliteration rates involves the deployment of biologically active rather than pure platinum coils. 146 Although uncontrolled studies suggest a potential reduction in the risk of recurrence, these data are preliminary and have yet to be confirmed in prospective controlled trials. 147, 148 Thus, although the short-term efficacy of endovascular coil obliteration is well established compared with microsurgical approaches, close long-term surveillance continues to be warranted, because durability remains a significant concern. 149 Given this delicate balance between safety and durability, there have been multiple efforts to identify subgroups of patients who might be best treated with endovascular or microsurgical techniques. Although the quality of the data is modest, most agree that with current endovascular technology, middle cerebral artery aneurysms can be difficult to treat with coil embolization, and in this location, surgical treatment has tended to yield more favorable results. 146,150 -152 Although some have suggested that older patients are ideal candidates for coiling rather than clipping, data on this population are sparse and at times conflicting. 141, 153, 154 Although patients presenting with an intraparenchymal hematoma Ͼ50 mL have a higher incidence of unfavorable outcome, hematoma evacuation within Ͻ3.5 hours has been shown to improve outcome in this subgroup and argues in favor of microsurgery for most patients with large parenchymal clots. 155 By contrast, patients presenting during the vasospasm period, especially those with confirmed vasospasm, may be better treated with endovascular techniques, depending on the anatomy of the aneurysm and its relationship to the spasm. 150 Patients presenting with poor clinical grade appear to benefit more from endovascular coiling, especially if they are also elderly, because advanced age renders long-term durability less important. 156 Still, it is critical that patients with poor clinical grade be treated in centers where both modalities are available. 157 Endovascular treatment of posterior circulation aneurysms has been gaining widespread acceptance based on several observational studies. A meta-analysis revealed that the mortality from coiling of a basilar bifurcation aneurysm was 0.9%, and the risk of permanent complications was 5.4%. 158 More recently, with regard to treatment of posterior circulation aneurysms, the mortality and morbidity in 112 ruptured aneurysms was 3.7% and 9.4%, respectively. 159 These data have led to an increasing tendency toward coiling ruptured posterior circulation aneurysms. One study that compared clipping versus coiling of basilar apex aneurysm (44 patients in each treatment arm) found a poor outcome rate of 11% in the endovascular treatment group versus 30% in the surgical group. In that study, the main difference was the rate of ischemia and hemorrhage during the surgical intervention. The rates of recurrent hemorrhage and delayed ischemia were actually similar in both groups. 159 Incomplete aneurysm occlusion and recurrent aneurysm filling from progressive coil compaction are particularly difficult challenges encountered with endovascular treatment of basilar artery aneurysms. In a study of 41 posterior circulation aneurysms, 35 (85%) had complete or nearcomplete immediate angiographic occlusion. The follow-up time frame for this study was 17 months, and of the 29 patients for whom follow-up was obtained, those with completely occluded aneurysms did not reveal any compaction. In the remaining patients who had near-complete occlusion, 47% had experienced recanalization, with 1 patient experiencing a rehemorrhage. 160 On the basis of these findings, closer follow-up with sequential DSA is needed in patients who undergo coiling of posterior circulation aneurysms, particularly those who do not exhibit complete occlusion on immediate follow-up angiography. 
Surgical and Endovascular Methods of
Hospital Characteristics and Systems of Care
In a US study of 31 476 nontraumatic cases of aSAH from 2003, definitive aneurysm repair was delivered in fewer than one third of cases. That said, the adjusted odds of definitive repair were significantly higher in urban teaching hospitals than in urban nonteaching hospitals (odds ratio, 1.62) or rural hospitals (odds ratio, 3.08). 7 In another study from 1993 to 2003, teaching status and larger hospital size were associated with higher charges and longer stay but also with better outcomes (PϽ0.05) and lower mortality rates (PϽ0.05), especially in patients who underwent aneurysm clipping (PϽ0.01). Endovascular treatment, which was more often used in the elderly, was also associated with significantly higher mortality rates in smaller hospitals (PϽ0.001) and steadily increasing morbidity rates (45%). Large academic centers were associated with better results, particularly for surgical clip placement. 161 Prior studies have also indicated that 82% of US hospitals admitted Ͻ19 patients with aSAH annually, and the 30-day mortality rate was significantly higher in hospitals that admitted Ͻ10 patients with aSAH versus Ͼ35 patients with aSAH (39% versus 27%; odds ratio, 1.4). 80 Two factors associated with better outcomes were greater use of endovascular services and a higher percentage of patients transferred from other hospitals. 79 -81 Institutions that used endovascular coil embolization more frequently had lower in-hospital mortality rates, a 9% reduction in risk for every 10% of cases treated. In addition, there was a 16% reduction in risk of in-hospital death at institutions that used interventional therapies such as balloon angioplasty to treat arterial vasospasm. 2, 81, 162 Therefore, hospital treatment volumes and availability of both endovascular and neurological intensive care services at hospitals are important determinants of improved outcomes in aSAH. 163 In addition, a cost-utility analysis estimated that transferring a patient with aSAH from a low-to a high-volume hospital would result in a gain of 1.6 quality-adjusted life-years at a cost of $10 548. 162, 163 Although 1 study suggested that care was uniformly delivered within an institution when weekend and weekday admissions were compared, 164 others have shown that intensive care specialists followed evidence-based recommendations very inconsistently, and these variations in practice did not depend on the quality of the supporting data. 165 Significant practice differences were noted between respondents from North America and Europe and between those working in high-and low-volume centers. Thus, the study demonstrated that the practices of intensive care unit physicians treating aSAH are heterogenous and often at variance with available evidence. 165 One recent effort to increase the uniformity of care is the development of an Accreditation Council on Graduate Medical Education-approved fellowship training program for endovascular surgical neuroradiology. 166 Another effort is legislation or regulation in Ͼ10 states that defines elements of comprehensive stroke centers and their role in networks and stroke systems of care. The Brain Attack Coalition paper that proposed the establishment of these centers included management of aSAH in its scope. 167 From the endovascular perspective, this expertise includes the ability to treat patients with intracranial aneurysms, SAH-induced vasospasm, brain arteriovenous malformations, and ischemic stroke. Other important required elements of these centers are vascular neurosurgical expertise, dedicated intensive care units, and 24/7 access to advanced neuroimaging. The rationale for comprehensive stroke centers is based on the success of similar models for trauma. 
Hospital Characteristics and Systems of
Anesthetic Management During Surgical and Endovascular Treatment
The general goals of anesthetic management involve hemodynamic control to minimize the risk of aneurysm rerupture and strategies to protect the brain against ischemic injury. Although induced hypotension has been used in the past to prevent aneurysm rupture, data suggest that there could be potential harm, with an increased risk of early and delayed neurological deficits. 168, 169 A retrospective study suggests that a decrease in mean arterial pressure of Ͼ50% is associated with poor outcome; however, after adjustment for age, this association was no longer statistically significant. 170 In patients undergoing cerebral aneurysm surgery, intraoperative hyperglycemia has been associated with long-term decline in cognition and gross neurological function. 171 These associations are seen at levels of hyperglycemia commonly encountered in practice, with increased risk of alterations in cognition with glucose concentrations Ͼ129 mg/dL and neurological deficits with glucose concentrations Ͼ152 mg/ dL. 171 Numerous pharmacological agents have been used to promote cerebral protection during cerebral aneurysm sur-gery, 172-181 but none have been clearly shown to improve outcome. Systemic hypothermia has been used in several clinical settings, including head injury, ischemic stroke, and circulatory arrest, to protect the brain against ischemic injury. [182] [183] [184] [185] [186] [187] [188] Use of hypothermia during craniotomy for the treatment of ruptured cerebral aneurysm was evaluated in a multicenter randomized, controlled trial. The study showed that hypothermia was relatively safe but was not associated with a beneficial effect in mortality or neurological outcome among patients with good-grade aSAH. 189 In addition, intraoperative hypothermia had no beneficial effect on neuropsychological function after SAH. 190 Of note, the power of these 2 studies was not sufficient to detect more modest benefits from hypothermia, and there were some trends in favor of hypothermia for secondary end points.
Temporary clipping is frequently used to improve surgical conditions and prevent intraoperative rupture during the surgical dissection of aneurysms. In a retrospective study, outcome was not affected by temporary vascular occlusion. 191 Induced hypertension can be considered when the duration of temporary clipping is expected to be Ͼ120 seconds, but the value of this strategy has not been well studied in aneurysm surgery. In selected patients with giant aneurysms, deep hypothermia with circulatory arrest under cardiopulmonary extracorporeal circulation has been shown to be a feasible and possibly useful technique, but outcome data are lacking. [192] [193] [194] [195] [196] Transient cardiac pause induced by adenosine has been used to control bleeding from intraoperative aneurysm rupture or to decompress large aneurysms and facilitate aneurysm clip application 197, 198 ; however, controlled studies are needed to validate this intervention.
There is little information in the literature about anesthetic management of patients undergoing endovascular treatment of ruptured cerebral aneurysms. 199 -201 Generally, the anesthetic principles that apply to open surgical treatment of ruptured cerebral aneurysms also apply to endovascular treatment. The choice of anesthetic technique varies depending on the institution, with the most common techniques being conscious sedation and general anesthesia. [202] [203] [204] There have been no studies comparing these 2 techniques. One of the main goals of the anesthetic technique is keeping the patient motionless to optimize the quality of the images used to perform the endovascular procedure; hence, general anesthesia with endotracheal intubation is often preferred for these procedures.
Intraprocedural aneurysm rupture during endovascular treatment presents a major challenge unlike that encountered with open craniotomy. There may be a sudden and massive rise in blood pressure with or without bradycardia attributable to an elevation in intracranial pressure. Hyperventilation and osmotic diuresis may be required to control the intracranial hypertension. Aggressive treatment of surges in blood pressure may induce ischemia; therefore, antihypertensive therapy should be reserved for patients with extreme elevations in blood pressure.
Endovascular procedures differ from open procedures in that anticoagulation with heparin is frequently administered during the embolization of aneurysms. Patients who have undergone anticoagulation require rapid reversal with protamine if intraprocedural aneurysm rupture occurs. With the increasing use of intravascular stents, the administration of antiplatelet agents (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor antagonists) during these procedures has become more common. In case of intraprocedural rupture, rapid reversal of antiplatelet activity can be attempted by platelet transfusion. 
Anesthetic Management During Surgical and
Induced hypothermia during aneurysm surgery is not routinely recommended but may be a reasonable option in selected cases (Class III; Level of Evidence B).
Prevention of intraoperative hyperglycemia during aneurysm surgery is probably indicated (Class IIa; Level of Evidence B).
The use of general anesthesia during endovascular treatment of ruptured cerebral aneurysms can be beneficial in selected patients (Class IIa; Level of Evidence C).
Management of Cerebral Vasospasm and DCI After aSAH
Narrowing (vasospasm) of the angiographically visible cerebral arteries after aSAH is common, occurring most frequently 7 to 10 days after aneurysm rupture and resolving spontaneously after 21 days. The cascade of events culminating in arterial narrowing is initiated when oxyhemoglobin comes in contact with the abluminal side of the vessel. 205 The pathways leading to arterial narrowing have been the focus of extensive basic research, but no effective preventive therapy has been developed to date. Part of the reason for this lack of success likely stems from the fact that vasospasm occurs at multiple levels in the arterial and arteriolar circulation. Large artery narrowing seen in angiographically visible vessels only results in ischemic neurological symptoms in 50% of cases, and although there is a correlation between the severity of large artery spasm and symptomatic ischemia, there are patients with severe large artery spasm who never become symptomatic and others with quite modest spasm who not only develop symptoms but go on to develop infarction. 206 Probably many factors contribute to the development of ischemia and infarction, including but not limited to distal microcirculatory failure, poor collateral anatomy, and genetic or physiological variations in cellular ischemic tolerance. 207, 208 DCI, especially that associated with arterial vasospasm, remains a major cause of death and disability in patients with aSAH. The management of aSAH-induced vasospasm is complex. Many significant advances in the understanding of aSAH-induced vasospasm and DCI have been made since publication of the previous version of these guidelines, which focused on prevention with oral nimodipine and maintenance of euvolemia, as well as treatment with triple-H therapy (hemodynamic augmentation therapy) and/or endovascular therapy with vasodilators and angioplasty balloons. First, the case for nimodipine is even stronger, with a recent comprehensive meta-analysis confirming improved neurological outcomes by preventing processes other than large-vessel narrowing. 209, 210 Although there have been sparse new important data on the lack of benefit for prophylactic hypervolemia compared with maintenance of euvolemia, new data show that both prophylactic angioplasty of the basal cerebral arteries and antiplatelet prophylaxis are ineffective in reducing morbidity. [211] [212] [213] Similarly, the only supportive data for the use of lumbar drainage come from a single case-control study, 214 although there is ongoing investigation on the value of this intervention to reduce arterial spasm and DCI. 214 The data are a bit better for intrathecal thrombolytic infusions, with a recent meta-analysis of 5 randomized, controlled trials suggesting a benefit despite some methodological weaknesses. 215, 216 There are also emerging data for several novel methods to reduce the incidence and ischemic consequences of aSAH-induced vasospasm. These new approaches are based on robust experimental data that indicate a critical role for endothelial dysfunction, particularly at the microcirculatory level. 217 Several recent clinical trials have investigated the utility of statins, endothelin-1 antagonists, and magnesium sulfate. 218 Statin agents have been studied in several small, single-center randomized trials with variable results. Although a recent meta-analysis reported no evidence for clinical benefit, 219 a larger phase 3 trial (SimvasTatin in Aneurysmal Subarachnoid Hemorrhage [STASH] ) is in progress. Clazosentan, an endothelin-1 receptor antagonist, had been shown to be associated with a dose-dependent reduction in the incidence of angiographic vasospasm in a phase IIb trial (Clazosentan to Overcome Neurological iSChemia and Infarct OccUrring after Subarachnoid hemorrhage [CONSCIOUS-1]). 220 A benefit for clinical outcomes was not initially apparent but then was judged present when a stricter definition of vasospasmrelated stroke was used. However, a subsequent trial (CONSCIOUS-2) that tested the drug in patients treated with aneurysm clipping found no improvement in clinical outcome in the clazosentan group. 221 A similar study in patients treated with coiling (CONSCIOUS-3) was then stopped before completion. Magnesium sulfate has been studied in several pilot trials. Although there is some suggestion of reduction in delayed ischemic deficits associated with magnesium infusion, a benefit has not been conclusively shown in a meta-analysis. 222 A phase 3 trial (Intravenous Magnesium sulfate for Aneurysmal Subarachnoid Hemorrhage [IMASH]) did not support any clinical benefit from magnesium infusion over placebo in aSAH. 223 A larger randomized trial is under way.
With regard to the diagnosis of DCI, which can often be problematic, it is increasingly clear that although serial neurological examinations are important, they are of limited sensitivity in patients with poor clinical grade. Therefore, the diagnostic approach needs to be tailored to the clinical situation. Various diagnostic tools are commonly used to identify (1) arterial narrowing and/or (2) perfusion abnormalities or reduced brain oxygenation. These different tools have advantages and disadvantages. Although comparative studies of diagnostic accuracy for large arterial narrowing have been performed for some modalities, no randomized trials have compared the impact of the use of different diagnostic methods on patient outcomes. That said, there are emerging data that perfusion imaging, demonstrating regions of hypoperfusion, may be more accurate for identification of DCI than anatomic imaging of arterial narrowing or changes in blood flow velocity by transcranial Doppler, for which the data are best for the middle cerebral artery territory. 224 -226 Perfusion CT is a promising technology, although repeat measurements are limited by the risks of dye load and radiation exposure. 226 When DCI is diagnosed, the initial treatment is the induction of hemodynamic augmentation to improve cerebral perfusion. No randomized trials of this intervention have been performed, but the rapid improvement of many patients with this therapy and their worsening when it is stopped prematurely are convincing proof of efficacy. The exact mechanism of benefit is unclear. In some patients, increased mean arterial pressures may increase cerebral blood flow in the setting of autoregulatory dysfunction. In others, there may be some direct transluminal pressure effect that leads to arterial dilation. 227 Traditionally, hemodynamic augmentation has consisted of hemodilution (a common occurrence in this population), hypervolemia, and hypertensive therapy. Accumulating literature has shifted the focus from this triple-H therapy to the maintenance of euvolemia and induced hypertension. 228 One novel method of hemodynamic augmentation under investigation is an aortic balloon device, approved under a humanitarian device exemption. 229 Endovascular intervention is often used in patients who do not improve with hemodynamic augmentation and those with sudden focal neurological deficits and focal lesions on angiography referable to their symptoms. 230 Interventions generally consist of balloon angioplasty for accessible lesions and vasodilator infusion for more distal vessels. Many different vasodilators are in use. In general, these are calcium channel blockers, but nitric oxide donors have been used in small series as well. 231 Papaverine is used less frequently because it can produce neurotoxicity. 232 The primary limitation of vasodilator therapy is the short duration of benefit. As with hemodynamic augmentation, there have been no randomized trials of these interventions, but large case series have demonstrated angiographic and clinical improvement. 233 
Management of Cerebral Vasospasm and DCI
Management of Hydrocephalus Associated With aSAH
Acute hydrocephalus occurs in 15% to 87% of patients with aSAH. 234 -240 Chronic shunt-dependent hydrocephalus, on the other hand, occurs in 8.9% to 48% of patients with aSAH. 234 -238,240 -244 There is only 1 randomized, controlled trial pertaining to the management of hydrocephalus associated with aSAH 245 and 2 meta-analyses 236, 243 ; the rest of the literature consists of nonrandomized case-control, case series, or case reports. Acute hydrocephalus associated with aSAH is usually managed by external ventricular drainage (EVD) or lumbar drainage. EVD for patients with aSAH-associated hydrocephalus is generally associated with neurological improvement. 246 -249 The risk of aneurysm rebleeding with EVD has been studied in 3 retrospective case series, 1 of which found a higher risk of rebleeding with EVD, 250 whereas the other 2 studies found no increased risk. 239, 251 Lumbar drainage for the treatment of aSAH-associated hydrocephalus has been reported to be safe (no increase in the risk of rebleeding), but it has only been examined in retrospective series, 214,252-255 1 of which specifically evaluated intraoperative lumbar drainage for brain relaxation. 256 The theoretical risk of tissue shift after placement of a lumbar drain in patients with severe intracranial hypertension should be considered when deciding what method of cerebrospinal fluid diversion to use, particularly in patients with associated intraparenchymal hematomas. When obstructive hydrocephalus is suspected, an EVD should be preferred. Preliminary data have suggested that lumbar drainage is associated with reduced incidence of vasospasm. 214, 255 Serial lumbar punctures to manage acute aSAH-associated hydrocephalus have been described as safe, but this strategy has only been assessed in small retrospective series. 239, 257 Chronic hydrocephalus associated with aSAH is usually treated with ventricular shunt placement. Only a proportion of patients with aSAH-associated acute hydrocephalus develop shunt-dependent chronic hydrocephalus. The method of determining which patients require ventricular shunt placement was studied in a single-center, prospective, randomized, controlled trial in which 41 patients were randomized to rapid weaning of EVD (wean period Ͻ24 hours) and 40 patients were randomized to gradual EVD weaning (wean period 96 hours). 245 There was no difference in the rate of shunt placement (63.4% rapid versus 62.5% gradual), but the gradual wean group had 2.8 more days in the intensive care unit (Pϭ0.0002) and 2.4 more days in the hospital (Pϭ0.0314). 245 A number of retrospective series have attempted to identify factors predictive of aSAH-associated shunt-dependent chronic hydrocephalus. 235, 236, 240, 242 A meta-analysis 236 of 5 nonrandomized studies 236,258 -261 with 1718 pooled patients (1336 who underwent clipping, 382 who underwent coiling) found a lower risk of shunt dependency in the clipping group (relative risk, 0.74; 95% confidence interval, 0.58 -0.94) than in the coiling group (Pϭ0.01); however, only 1 of the 5 studies showed an independent significant difference. 258 Three other nonrandomized series not included in the metaanalysis showed no significant difference between clipping and coiling in shunt-dependent chronic hydrocephalus. 237, 244, 262 Fenestration of the lamina terminalis has been suggested to reduce the incidence of shunt-dependent chronic hydrocephalus, yet a meta-analysis 243 of 11 nonrandomized studies 234, 260, [263] [264] [265] [266] [267] [268] [269] [270] [271] pooled 1973 patients (975 who had undergone fenestration and 998 who had not) and found no significant difference in shunt-dependent hydrocephalus between patients who had undergone fenestration of the lamina terminalis and those who had not (10% in the fenestrated cohort versus 14% in the nonfenestrated cohort; Pϭ0.09). A nonrandomized study not included in the meta-analysis compared 95 patients who underwent aneurysm clipping, cisternal blood evacuation, and lamina terminalis fenestration with 28 comparable, non-blood-cleansed, endovascular therapytreated patients and found that shunt-dependent hydrocephalus occurred in 17% of surgical patients versus 33% of patients treated with endovascular therapy (statistical significance not reported). 237 
Management of Hydrocephalus
Management of Seizures Associated With aSAH
The incidence, future implications, and management of seizures associated with aSAH are controversial. At present, no randomized, controlled trials are available to guide decisions on prophylaxis or treatment of seizures. 2, 272 A relatively high percentage of aSAH patients (as many as 26%) experience seizure-like episodes, 99, 272, 273 but it remains unclear whether these episodes are verifiably epileptic in origin. 99, 274 More recent retrospective reviews suggest a lower seizure incidence of 6% to 18%, [275] [276] [277] [278] and 2 of these studies 276, 278 found that the majority of such patients reported onset of seizure occurring before medical evaluation. Delayed seizures occurred in 3% to 7% of patients. 276, 278 Retrospective studies have identified several risk factors for the development of early seizures associated with aSAH, including aneurysm in the middle cerebral artery, 279 thickness of aSAH clot, 276 associated intracerebral hematoma, 280 -282 rebleeding, 276 infarction, 283 poor neurological grade, 276 and history of hypertension. 98 The mode of treatment for patients with ruptured aneurysms also appears to influence the subsequent development of seizures. One study of patients treated by endovascular means reported no periprocedural seizures and a delayed seizure rate of 3%. 284 Moreover, extended follow-up of patients enrolled in the ISAT demonstrated a significantly lower incidence of seizures in patients treated with endovascular coiling. 140 The association between seizures and functional outcome remains unclear. Some studies have reported no impact on outcome, 276, 278 whereas others found seizures to be independently associated with worse outcome. 275 Two recent large, retrospective, single-institution studies of patients with aSAH found that nonconvulsive status epilepticus is a very strong predictor of a poor outcome. 285, 286 Although high-quality evidence for routine anticonvulsant use in aSAH is lacking, short-term prophylactic antiepileptic therapy is still commonly used in patients with aSAH, 274, 276, 278 based on the argument that seizures in acutely ill patients with aSAH could lead to additional injury or rebleeding from an unsecured aneurysm. Evidence from a few relatively small nonrandomized studies of craniotomy patients supports this position, 281, 282, 287 but the efficacy of routine use of anticonvulsants in patients with aSAH managed with microsurgical techniques remains unproven. 288 -290 Any purported benefit of routine anticonvulsant use in aSAH must be tempered by a consideration of the potential risks of such use. In 1 large single-institution study in which anticonvulsants were used routinely, adverse drug effects were seen in 23% of patients. 276 Another single-center retrospective study found that the use of prophylactic phenytoin was independently associated with a worse cognitive outcome at 3 months after aSAH. 291 Data pooled from trials of the impact of other therapies also suggest a worse outcome in those treated with anticonvulsants, but use of anticonvulsants was also associated with vasospasm, DCI, and fever, which suggests that there may have been bias in who was treated with antiepileptic drugs. 292 Although retrospective studies have not demonstrated a benefit for use of prophylactic anticonvulsants after aSAH, 273, 288 the studies were small and hampered by limitations (eg, anticonvulsant levels were not routinely monitored). 2, 273, 288 
Management of Seizures
Management of Medical Complications Associated With aSAH
Both hypernatremia and hyponatremia are frequently observed in the acute phase after aSAH. 293, 294 The reported incidence of hyponatremia in this disease ranges from 10% to 30%. Hyponatremia has been chronologically associated with the onset of sonographic and clinical vasospasm. 295, 296 Hyponatremia can develop from different mechanisms after aSAH. The syndrome cerebral salt wasting is produced by excessive secretion of natriuretic peptides and causes hyponatremia from excessive natriuresis, which may also provoke volume contraction. 297 The diagnosis of cerebral salt wasting is more common in patients with poor clinical grade, ruptured anterior communicating artery aneurysms, and hydrocephalus, and it may be an independent risk factor for poor outcome. 298 -300 Uncontrolled studies using crystalloid or colloid agents suggest that aggressive volume resuscitation can ameliorate the effect of cerebral salt wasting on the risk of cerebral ischemia after aSAH. 301, 302 One retrospective study has suggested that 3% saline solution is effective in correcting hyponatremia in this setting. 303 In addition, use of hypertonic saline solution appears to increase regional cerebral blood flow, brain tissue oxygen, and pH in patients with high-grade aSAH. 304 Two randomized, controlled trials have been performed to evaluate fludrocortisones to correct hyponatremia and fluid balance. One trial found that it helped to correct the negative sodium balance, and the other reported a reduced need for fluids and improved sodium levels using this mineralocorticoid. 305, 306 A similar randomized, placebo-controlled trial showed reduced natriuresis and a lower rate of hyponatremia in aSAH patients treated with hydrocortisone. 307 The value of albumin as an efficient volume expander during the vasospasm phase in aSAH has been suggested in uncontrolled studies, but there is no clear evidence of its superiority over crystalloids in patients with aSAH. 308 Fever is the most common medical complication in aSAH. 309 The presence of fever of noninfectious (central) origin has been associated with severity of injury, amount of hemorrhage, and development of vasospasm, and it may represent a marker of a systemic inflammatory state triggered by blood and its byproducts. 310 -312 Analysis of data from a prospectively collected registry of aSAH indicated that fever was independently associated with worse cognitive outcome in survivors of aSAH. 313, 314 Improved functional outcome with effective control of fever has been reported. 315 Both animal studies and human case series have demonstrated an association between elevated blood glucose concentration and poor outcome after ischemic brain injury. 316 -323 The mechanisms explaining such an association in human beings are unclear. Data obtained from consecutive patients with aSAH using historical controls to compare aggressive versus standard management of hyperglycemia suggest that effective glucose control after aSAH can significantly reduce the risk of poor outcome in these patients. 324 Nevertheless, even serum glucose levels within the normal range may be associated with brain energy metabolic crisis and lactate-pyruvate ratio elevation in patients with poor-grade aSAH. 325 Anemia is common after aSAH and may compromise brain oxygen delivery. 326 Transfusion of red blood cells in anemic patients with aSAH results in a significant rise in cerebral oxygen delivery and a reduction in oxygen extraction ratio. 327 Data obtained from prospective registries of patients with aSAH suggest that higher hemoglobin values are associated with improved outcomes after aSAH. 328, 329 Nevertheless, thresholds for blood transfusion have been dictated in a nonsystematic manner and have therefore varied widely. Furthermore, red blood cell transfusions, as used in daily practice, have been associated with worse outcomes in aSAH in some series. 330, 331 Recently, a prospective randomized trial has shown the safety and feasibility of keeping a higher hemoglobin goal in patients with aSAH who are at high risk of vasospasm. 332 The optimal hemoglobin goal after aSAH is not yet known, however.
Two additional medical complications are heparin-induced thrombocytopenia [333] [334] [335] and deep venous thrombosis. With regard to the former, the incidence, based on 3 single-center series, is likely Ϸ5% and does not appear to be related to the use of heparin for deep venous thrombosis prophylaxis, but rather to the number of angiographic procedures performed. Patients with heparin-induced thrombocytopenia type II appear to have higher rates of thrombotic complications and symptomatic vasospasm/DCI, more deaths, and significantly less favorable outcomes. It is currently unclear whether there is a practical means of preventing heparin-induced thrombocytopenia, given the need for heparin in many angiographic procedures, but it is clearly important to recognize this complication to avoid further heparin exposure and to use instead a nonheparin alternative under the guidance of a hematologist. 336 By comparison, deep venous thrombosis has long been recognized as a relatively frequent occurrence after aSAH, especially in patients immobilized because of poor mental status. 337, 338 Nevertheless, in examining cohorts in which routine prophylaxis (subcutaneous heparinoids and external pneumatic compression sleeves) was used, recent data suggest that although screening protocols may identify additional cases of asymptomatic thrombosis, there is no significant difference in the incidence of pulmonary embolism between those screened and those not screened. 
Management of Medical Complications
Summary and Conclusions
The management of aSAH is a complex undertaking, and the current state of knowledge is in rapid evolution. This update, which is based on a mere 42 months of publications, identified 22 new recommendations (Table 4) , 5 of which were Class I recommendations. There were also 9 changes in prior recommendations. In total, there are now 22 Class I recommendations (Table 3) . Although these data show that frequent revision of these guidelines is clearly needed, the data presented here only begin to scratch the surface of the burgeoning knowledge in this fast-developing field. Those faced with managing these patients will thus do well to use these guidelines as merely the starting point for doing everything possible to improve the outcomes of patients with aSAH. This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all writing group members are required to complete and submit. A relationship is considered to be "significant" if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.
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